A Phase I Dose Escalation Study of Oral MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors.

Trial Profile

A Phase I Dose Escalation Study of Oral MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2014

At a glance

  • Drugs MK 2206 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 06 Mar 2012 Actual patient number changd from 72 to 104 according to ClinicalTrials.gov.
    • 09 Feb 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 09 Aug 2011 Planned End Date changed from 1 Aug 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top